Norwegian pharmaceutical company Navamedic ASA (OSE:NAVA) said on Friday that it has signed an exclusive distribution agreement with German pharmaceutical company Evolsin Medical to expand its business into Germany.

The first product to launch under the partnership will be Navamedic's antiperspirant, Dermix Absolut Torr, marketed locally as Evolsin 7-Tage Antitranspirant.

Developed and manufactured in Sweden, the product is classified as a cosmetic and will be available in roll-on, dab-on, and wipe formats. Dermix Absolut Torr is already sold in the Nordics, the Middle East, and the Balkans, and is also known under the brand name Dermix Absolut Dry.

Germany, with a population of 84 million, will be the largest market launch for the product to date, expected in early 2026.

Navamedic CEO Kathrine Gamborg Andreassen welcomed the partnership with Evolsin and said that it opens opportunities for additional product launches in the German market.